As the field of oncology evolves, we need to shift away from traditional binary “yes-no” biomarkers to a more nuanced, spatial understanding of tumor biology. This approach will allow for more personalized treatment plans that are tailored to the unique characteristics of each patient’s tumor.
By leveraging AI and machine learning, researchers can analyze complex data sets, identify novel biomarkers, and provide more effective and tailored treatment options for cancer patients.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.
With the information contained in a simple 30-second voice sample, providers can help patients get ahead of future health issues and prescribe or adjust treatment plans as needed.
Blending computational biology and AI-based methods, the goal is to identify new targets, pair these with effective chemistry, and define biomarkers to optimally position novel therapies.
Before the pandemic started, the U.S. Department of Defense and Philips designed a system to detect potential infections before symptoms appear. Now, they’re turning it on the Covid-19 pandemic.
The FDA approved Keytruda as a single agent for patients with first-line metastatic or unresectable colorectal cancer that carries the biomarker MSI-H or dMMR. The drug was the first to win a biomarker-based, tumor-agnostic label, in 2017.
Alan Murray on improving access for medical transportation.
Integrating the NCCN's Biomarker Compendium data into Syapse's products is designed to aid finding targeted drugs and clinical trials while improving physician workflow.
Lower costs for capital and sequencing, a friendlier regulatory and reimbursement environment and growth in precision medicine are among driving factors.
Forecast of significant growth in market comes after Roche acquired remaining stake in Foundation Medicine last month.
If approved, LOXO-101 (larotrectinib) would be the second drug to win a biomarker-based label, after Merck's Keytruda.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
It is the latest in a series of developments for diagnostics business Owlstone Medical, which recently brought its breath biopsy kits to market.
The number of digital health apps has doubled in recent years to 318,000. Increased clinical validation has led to wider adoption of apps and sensors by pharma companies and healthcare systems to remotely monitor patients and quantify medication adherence.
There's still a gap between potential and validation when it comes to digital biomarkers.
The biomarker market is booming, and it's projected to keep soaring significantly.
For diseases like Parkinson’s and Alzheimer’s, it seems like symptoms are a function of what’s going on deep down inside of whoever is afflicted – a reflection of something happening at the core. But what if detection could be right in front of our faces, just on the surface of a patient’s skin? Dr. Ildefonso […]